159 related articles for article (PubMed ID: 15577134)
1. [Additional effect of SERM: central nervous system].
Honjo H
Clin Calcium; 2004 Oct; 14(10):69-72. PubMed ID: 15577134
[TBL] [Abstract][Full Text] [Related]
2. Cognitive function in postmenopausal women treated with raloxifene.
Yaffe K; Krueger K; Sarkar S; Grady D; Barrett-Connor E; Cox DA; Nickelsen T;
N Engl J Med; 2001 Apr; 344(16):1207-13. PubMed ID: 11309635
[TBL] [Abstract][Full Text] [Related]
3. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
4. [Raloxifene: a selective modulator of estrogen receptors].
van den Brûle FA; Kalbus MF; Gaspard UJ
J Gynecol Obstet Biol Reprod (Paris); 1999 Dec; 28(8):788-99. PubMed ID: 10635481
[TBL] [Abstract][Full Text] [Related]
5. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
Lee WL; Chao HT; Cheng MH; Wang PH
Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
[TBL] [Abstract][Full Text] [Related]
6. The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial.
Haskell SG; Richardson ED
Conn Med; 2004; 68(6):355-8. PubMed ID: 15266884
[TBL] [Abstract][Full Text] [Related]
7. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
Higuchi T; Mizunuma H
Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
[TBL] [Abstract][Full Text] [Related]
8. [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].
Hosoi T
Clin Calcium; 2007 Sep; 17(9):1419-23. PubMed ID: 17767033
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
10. Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.
Huerta-Ramos E; Iniesta R; Ochoa S; Cobo J; Miquel E; Roca M; Serrano-Blanco A; Teba F; Usall J
Eur Neuropsychopharmacol; 2014 Feb; 24(2):223-31. PubMed ID: 24342775
[TBL] [Abstract][Full Text] [Related]
11. [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].
Kastelan D; Korsić M
Reumatizam; 2005; 52(2):67-70. PubMed ID: 16689133
[TBL] [Abstract][Full Text] [Related]
12. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
Shintani M
Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
[TBL] [Abstract][Full Text] [Related]
13. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
14. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
15. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
16. The science of selective estrogen receptor modulators: concept to clinical practice.
Jordan VC
Clin Cancer Res; 2006 Sep; 12(17):5010-3. PubMed ID: 16951214
[No Abstract] [Full Text] [Related]
17. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
Simoncini T; Mannella P; Genazzani AR
Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
[TBL] [Abstract][Full Text] [Related]
19. Raloxifene for prevention of osteoporotic fractures.
Diehr S; Mijal S; Nashelsky J
Am Fam Physician; 2005 Jul; 72(1):132-4. PubMed ID: 16035693
[No Abstract] [Full Text] [Related]
20. [Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].
MMW Fortschr Med; 2003 Jul; 145(27-28):63. PubMed ID: 14587198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
